title: Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.
authors.affiliation: Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Rea
authors.affiliation: 1] Médecine vasculaire, Hôpital européen Georges Pompidou, AP-HP, Paris, France [2] INSERM UMR970, PARCC, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
authors.forename: T
authors.initials: T
authors.lastname: Mirault
authors.affiliation: Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Raffoux
authors.affiliation: Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Boissel
authors.affiliation: Centre d'Investigation Clinique, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: A L
authors.initials: AL
authors.lastname: Andreoli
authors.affiliation: Hématologie et Oncologie, Hôpital André Mignot, Université de Versailles, Le Chesnay, France.
authors.forename: P
authors.initials: P
authors.lastname: Rousselot
authors.affiliation: Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Dombret
authors.affiliation: 1] Médecine vasculaire, Hôpital européen Georges Pompidou, AP-HP, Paris, France [2] INSERM UMR970, PARCC, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Messas
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications* / Q000175:diagnosis; D017326:Clinical Trials, Phase III as Topic; D004252:DNA Mutational Analysis; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C498826:nilotinib